Faucette Stephanie R, Zhang Tong-Cun, Moore Rick, Sueyoshi Tatsuya, Omiecinski Curtis J, LeCluyse Edward L, Negishi Masahiko, Wang Hongbing
Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
J Pharmacol Exp Ther. 2007 Jan;320(1):72-80. doi: 10.1124/jpet.106.112136. Epub 2006 Oct 13.
Both the human pregnane X receptor (hPXR) and constitutive androstane receptor (hCAR) are capable of regulating CYP3A4 and CYP2B6 gene expression. However, the majority of currently identified CYP3A4 and CYP2B6 inducers are confirmed activators of hPXR but not hCAR. To compare these receptors with respect to their chemical selectivities, 16 drugs known to induce CYP3A4 and/or CYP2B expression were evaluated for relative activation of hPXR versus hCAR. Because of the high basal but low chemical-induced activation of hCAR in immortalized cells, alternative methods were used to evaluate hCAR activation potential. Thirteen of the 16 compounds were classified as moderate to strong hPXR activators. In contrast, carbamazepine (CMZ), efavirenz (EFV), and nevirapine (NVP) were classified as negligible or weak hPXR activators at concentrations associated with efficacious CYP2B6 reporter or endogenous gene induction in primary human hepatocytes, suggesting potential activation of hCAR. Subsequent experiments demonstrated that these three drugs efficiently induced nuclear accumulation of in vivo-transfected enhanced yellow fluorescent protein-hCAR and significantly increased expression of a CYP2B6 reporter gene when hCAR was expressed in CAR-/- mice. In addition, using a recently identified, chemically responsive splice variant of hCAR (hCAR3), the hCAR activation profiles of the 16 compounds were evaluated. By combining results from the hPXR- and hCAR3-based reporter gene assays, these inducers were classified as hPXR, hCAR, or hPXR/hCAR dual activators. Our results demonstrate that CMZ, EFV, and NVP induce CYP2B6 and CYP3A4 preferentially through hCAR and that hCAR3 represents a sensitive tool for in vitro prediction of chemical-mediated human CAR activation.
人孕烷X受体(hPXR)和组成型雄甾烷受体(hCAR)均能够调节CYP3A4和CYP2B6基因的表达。然而,目前已鉴定出的大多数CYP3A4和CYP2B6诱导剂都是hPXR的确认激活剂,而非hCAR的激活剂。为了比较这些受体在化学选择性方面的差异,对16种已知可诱导CYP3A4和/或CYP2B表达的药物进行了评估,以确定它们对hPXR和hCAR的相对激活作用。由于hCAR在永生化细胞中的基础激活水平较高但化学诱导激活水平较低,因此采用了替代方法来评估hCAR的激活潜力。16种化合物中有13种被归类为中度至强效的hPXR激活剂。相比之下,在原代人肝细胞中,与有效诱导CYP2B6报告基因或内源性基因相关的浓度下,卡马西平(CMZ)、依非韦伦(EFV)和奈韦拉平(NVP)被归类为可忽略不计或微弱的hPXR激活剂,这表明它们可能激活hCAR。后续实验表明,当在CAR-/-小鼠中表达hCAR时,这三种药物可有效诱导体内转染的增强型黄色荧光蛋白-hCAR的核积累,并显著增加CYP2B6报告基因的表达。此外,利用最近鉴定出的hCAR的化学响应性剪接变体(hCAR3),评估了这16种化合物的hCAR激活谱。通过结合基于hPXR和hCAR3的报告基因检测结果,这些诱导剂被归类为hPXR、hCAR或hPXR/hCAR双重激活剂。我们的结果表明,CMZ、EFV和NVP优先通过hCAR诱导CYP2B6和CYP3A4,并且hCAR3是体外预测化学介导的人CAR激活的敏感工具。